Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations

Detalles Bibliográficos
Autores principales: Satoh, Hiroaki, Miyazaki, Kunihiko, Sato, Yoshiharu, Hizawa, Nobuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Turkish Thoracic Society 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524493/
https://www.ncbi.nlm.nih.gov/pubmed/35957568
http://dx.doi.org/10.5152/TurkThoracJ.2022.22034
_version_ 1784800518481117184
author Satoh, Hiroaki
Miyazaki, Kunihiko
Sato, Yoshiharu
Hizawa, Nobuyuki
author_facet Satoh, Hiroaki
Miyazaki, Kunihiko
Sato, Yoshiharu
Hizawa, Nobuyuki
author_sort Satoh, Hiroaki
collection PubMed
description
format Online
Article
Text
id pubmed-9524493
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Turkish Thoracic Society
record_format MEDLINE/PubMed
spelling pubmed-95244932022-10-13 Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations Satoh, Hiroaki Miyazaki, Kunihiko Sato, Yoshiharu Hizawa, Nobuyuki Turk Thorac J Letter to the Editor Turkish Thoracic Society 2022-09-01 /pmc/articles/PMC9524493/ /pubmed/35957568 http://dx.doi.org/10.5152/TurkThoracJ.2022.22034 Text en Turkish Thoracic Society https://creativecommons.org/licenses/by-nc/4.0/Content of this journal is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. (https://creativecommons.org/licenses/by-nc/4.0/)
spellingShingle Letter to the Editor
Satoh, Hiroaki
Miyazaki, Kunihiko
Sato, Yoshiharu
Hizawa, Nobuyuki
Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations
title Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations
title_full Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations
title_fullStr Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations
title_full_unstemmed Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations
title_short Response to Afatinib in a Common EGFR-Mutated Lung Adenocarcinoma with a Very Rare Combination of Compound Mutations
title_sort response to afatinib in a common egfr-mutated lung adenocarcinoma with a very rare combination of compound mutations
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9524493/
https://www.ncbi.nlm.nih.gov/pubmed/35957568
http://dx.doi.org/10.5152/TurkThoracJ.2022.22034
work_keys_str_mv AT satohhiroaki responsetoafatinibinacommonegfrmutatedlungadenocarcinomawithaveryrarecombinationofcompoundmutations
AT miyazakikunihiko responsetoafatinibinacommonegfrmutatedlungadenocarcinomawithaveryrarecombinationofcompoundmutations
AT satoyoshiharu responsetoafatinibinacommonegfrmutatedlungadenocarcinomawithaveryrarecombinationofcompoundmutations
AT hizawanobuyuki responsetoafatinibinacommonegfrmutatedlungadenocarcinomawithaveryrarecombinationofcompoundmutations

Ejemplares similares